[CAS NO. 835904-51-3] Synta66
PRODUCTS SPECIFICATIONS [835904-51-3]
DESCRIPTION [835904-51-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 352.36 |
| Molecular Formula | C20H17FN2O3 |
| SMILES | O=C(C1=C(F)C=NC=C1)NC2=CC=C(C3=CC(OC)=CC=C3OC)C=C2 |
2 Publications Citing Use of MCE
Summary
Synta66 is an inhibitor of store-operated calcium entry channel Orai , which forms the pore of the CRAC channel, and used for the research of neurological disease .
IC50 & Target
Orai [1]
In Vitro
Synta66 is an inhibitor of Orai, which forms the pore of the CRAC channel. Synta66 (10 μM) attenuates peak SOCE in Müller glia. Synta66 (10 μM) prevents orai channels mediating the residual SOC current in Trpc1 −/− Müller cells [1] . Synta66 (10 μM) nearly completely blocks the Ca 2+ entry signal evoked by CaCl 2 addition, whereas it moderately reduces Ca 2+ mobilization from stores with 10% to 30% in platelet. Synta66 (10 μM) suppresses human platelet activation in plasma and whole-blood thrombus formation. Synta66 (10 μM) also inhibits murine platelet responses and thrombus formation [2] . Synta66 (10 μM) inhibits LAD2 human mast cell line. Synta66 (10 μM) significantly inhibits FcεRI stimulated histamine and TNFα secretion, and has differential effects on FcεRI stimulated prostaglandin D2 and cytokine release in human lung mast cells (HLMCs) [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 77.5 mg/mL ( 219.95 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8380 mL | 14.1900 mL | 28.3801 mL |
| 5 mM | 0.5676 mL | 2.8380 mL | 5.6760 mL |
| 10 mM | 0.2838 mL | 1.4190 mL | 2.8380 mL |
References
- [1] Molnár T, et al. Store-Operated Calcium Entry in Müller Glia Is Controlled by Synergistic Activation of TRPC and Orai Channels. J Neurosci. 2016 Mar 16;36(11):3184-98.
- [2] van Kruchten R, et al. Antithrombotic potential of blockers of store-operated calcium channels in platelets. Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1717-23.
- [3] Wajdner HE, et al. Orai and TRPC channel characterization in FcεRI-mediated calcium signaling and mediator secretion in human mast cells. Physiol Rep. 2017 Mar;5(5).